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ABSTRACT
Several vascular disorders, such as aberrant angiogenesis,
atherosclerosis and pulmonary hypertension, have been linked to
dysfunctional BMP signaling. Vascular hyperpermeability via
distortion of endothelial cell adherens junctions is a common
feature of these diseases, but the role of BMPs in this process has
not been investigated. BMP signaling is initiated by binding of ligand
to, and activation of, BMP type I (BMPRI) and type II (BMPRII)
receptors. Internalization of VE-cadherin as well as c-Src kinase-
dependent phosphorylation have been implicated in the loosening of
cell–cell contacts, thereby modulating vascular permeability. Here we
demonstrate that BMP6 induces hyperpermeabilization of human
endothelial cells by inducing internalization and c-Src-dependent
phosphorylation of VE-cadherin. Furthermore, we show BMP-
dependent physical interaction of VE-cadherin with the BMP
receptor ALK2 (BMPRI) and BMPRII, resulting in stabilization of the
BMP receptor complex and, thereby, the support of BMP6-Smad
signaling. Our results provide first insights into the molecular
mechanism of BMP-induced vascular permeability, a hallmark of
various vascular diseases, and provide the basis for further
investigations of BMPs as regulators of vascular integrity, both
under physiological and pathophysiological conditions.
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INTRODUCTION
Endothelial cells line the lumen of blood vessels and form a semi-
permeable monolayer that controls blood–tissue exchange of fluids,
plasma proteins and cells. Thus, the integrity of the endothelial
barrier is essential for physiological tissue homeostasis, and
hyperpermeability is involved in the progression of several
pathological conditions, including inflammation, atherosclerosis
and cancer (Davignon and Ganz, 2004; Weis and Cheresh, 2005).
Vascular permeability is mainly regulated by two mechanisms:
transcellular and paracellular permeability. During transcytosis,
macromolecules pass individual endothelial cells via specialized
vesicles containing caveolin-1 (Bauer et al., 2005) or
transmembrane channels formed by fused vesiculo-vacuolar
organelles (VVOs) (Dvorak et al., 1996). Paracellular
permeability is mediated by the dynamic opening of
interendothelial cell junctions that allow large proteins and cells to
enter the surrounding tissue. Alterations of cell–cell adhesion,
mainly mediated by tight (TJs) and adherens (AJs) junctions, is a
hallmark of paracellular permeability (Goddard and Iruela-Arispe,
2013). TJs mediate intercellular adhesion by the formation of
complexes between several members of the claudin, occludin and
junctional adhesion molecule (JAM) protein families and have been
implicated in the regulation of the blood–brain barrier (Luissint
et al., 2012). Vascular hyperpermeability in the microvasculature
has been repeatedly linked to changes in AJ architecture. AJs are
mainly formed by calcium-dependent interactions of vascular
endothelial cadherins (VE-cadherins, also known as cadherin 5 or
CD144) between neighboring cells. VE-cadherin is a single-span
transmembrane protein exclusively expressed by endothelial cells
and its extracellular domain forms homomeric dimers with VE-
cadherin molecules of adjacent cells (Bravi et al., 2014). The
cytoplasmic domain of VE-cadherin interacts with members of
the actin-binding catenin family and thus links VE-cadherin to
the cytoskeleton (Lampugnani et al., 1995; Iyer et al., 2004). VE-
cadherin is the main component of endothelial AJs and homophilic
VE-cadherin interactions have been reported to regulate vascular
permeability. Among these regulatory mechanisms, internalization
and tyrosine phosphorylation of VE-cadherin are strongly
associated with impaired barrier function. It has been shown that
vascular endothelial growth factor (VEGF, also known as VEGFA),
a potent permeability-inducing agent, triggers VE-cadherin
internalization (Gavard and Gutkind, 2006). Internalized VE-
cadherin enters endosomal compartments and is either recycled to
the plasma membrane or degraded (Xiao et al., 2003a, 2005).
Hence, the promotion of VE-cadherin internalization controls
permeability in a reversible manner. In addition, several studies
have demonstrated that other permeabilizing agents, such as tumor
necrosis factor α (TNF-α) (Angelini et al., 2006) and histamine
(Andriopoulou et al., 1999), modulate AJ stability by tyrosine
phosphorylation of VE-cadherin. It was shown that members of the
Src kinase family phosphorylate VE-cadherin (Eliceiri et al., 1999)
and Tyr685 of VE-cadherin was identified as a unique target site for
c-Src in vitro (Wallez et al., 2007). Recently, it has been reported
that phosphorylation at Tyr685 controls vascular permeability in
vivo, while phosphorylation at Tyr731 regulates leukocyte
diapedesis (Wessel et al., 2014). This highlights that
modifications of VE-cadherin allow diverse alterations of AJ
architecture and thereby dynamic disruptions of the endothelial cell
barrier. This diversity is necessary considering that plasma protein
and cell extravasation require openings of different sizes.
Besides controlling endothelial barrier function, VE-cadherin has
been implicated in the regulation of growth factor signaling. VE-
cadherin interacts with VEGFR2 (also known as KDR), and VE-
cadherin clusters retain VEGFR2 at the plasma membrane
(Lampugnani et al., 2006). Moreover, VE-cadherin has beenReceived 1 September 2015; Accepted 16 November 2015
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implicated in the regulation of transforming growth factor β (TGF-
β)-mediated inhibition of endothelial cell proliferation and
migration (Rudini et al., 2008). It has been shown that VE-
cadherin interacts with the TGF-β type I receptors activin receptor-
like kinase 1 and 5 (ALK1 and ALK5, also known as ACVRL1 and
TGFβR1, respectively), as well as the type II receptor (TGFβRII, or
TGFβR2) and functions as a positive regulator of TGF-β signal
transduction.
Bone morphogenetic proteins (BMPs) belong to the TGF-β
family of secreted growth factors, which comprises more than 30
structurally related ligands that are tissue-specifically expressed and
regulated by natural antagonists. BMPs bind to transmembrane
serine/threonine kinase receptors and the signal is transduced into
the cytosol via a heteromeric receptor complex of type I and type II
receptors. Receptor complex activation results in induction of
distinct intracellular signaling cascades: the canonical Smad and
non-Smad pathways. Once receptor-regulated Smads (R-Smads,
SMAD1/5/8) are activated upon phosphorylation by a type I
receptor, they form a complex with the commonmediator Smad (co-
Smad, SMAD4) to function as transcription factors and, together
with transcriptional co-activators and co-repressors, regulate the
expression of BMP target genes such as ID1 (Sieber et al., 2009).
BMP signal transduction is implicated in the regulation of
physiological as well as pathological processes of the endothelium.
Interestingly, altered BMP signaling has been observed during acute
inflammation, atherosclerosis and metastasis (Cai et al., 2012; Dyer
et al., 2014). A common hallmark of these diseases is vascular
hyperpermeability, causing plasma proteins or cells to enter the
surrounding tissue, leading to the formation of edema, plaques or
metastases (Kumar et al., 2009; Reymond et al., 2013). However,
the precise function of BMP signaling in the regulation of
endothelial cell permeability remains elusive. We have
investigated whether BMP signal transduction controls the
permeability of human umbilical vein endothelial cell (HUVEC)
monolayers and demonstrate that BMP6 induces hyperpermeability
by promotion of VE-cadherin internalization as well as c-Src-
mediated tyrosine phosphorylation. Furthermore, we identify VE-
cadherin as a novel regulator of vascular BMP signal transduction
and show that VE-cadherin physically associates with the BMP type
I receptor activin receptor-like kinase 2 (ALK2, also known as
ACVR1) and the BMP type II receptor (BMPRII, or BMPR2) in a
BMP6-dependent manner and that it stabilizes receptor complex
formation.
RESULTS
BMP6 induces hyperpermeability and disruption of AJ
architecture
To assess the effects of BMP signaling on vascular permeability, we
measured solute flux across an endothelial cell monolayer.
HUVECs were seeded onto collagen-coated transwell inserts and
stimulated with BMP6 or VEGF-165 (a variant of VEGF-A) for
24 h. Subsequently, flux of high molecular weight FITC-Dextran
across the monolayer was measured. We found that BMP6
stimulation led to a 2.7-fold increase in paracellular permeability,
similar to the potent permeability-inducing growth factor VEGF-
165 (Fig. 1A). When a pharmacological BMP type I receptor kinase
inhibitor (LDN-193189) (Cuny et al., 2008) was administered
60 min before BMP6 stimulation, BMP6-mediated permeability
was inhibited, suggesting that active BMPRI kinase is important for
this process. Thus, we hypothesized that BMP6-induced
permeability required signal transduction downstream of the BMP
receptors. A co-stimulation with BMP6 and VEGF-165 showed no
synergistic effects. These data suggested that BMP signaling
specifically induced permeability of an endothelial cell monolayer.
We next addressed the kinetics of BMP-induced permeability by
measuring changes in transendothelial electrical resistance (TEER).
Fig. 1. BMP6 induces vascular permeability in vitro. (A) BMP6 increases
endothelial cell monolayer solute permeability. HUVECs seeded in transwell
inserts were subjected to 10 nM BMP6 or 2 nM VEGF-165 and, as indicated,
pharmacological inhibitor (0.5 µM LDN-193189) treatment for 24 h and in vitro
transendothelial solute permeability was measured by FITC-Dextran flux.
Mean±s.e.m. normalized to untreated control cells from ten biological
replicates in three independent experiments. (B) BMP6 stimulation decreases
transendothelial electrical resistance (TEER). HUVECs were seeded in
transwell inserts and stimulated with growth factors for 24 h. At the indicated
time points, TEER was measured. Mean±s.d. normalized to untreated control
cells from nine biological replicates in three independent experiments.
(A,B) ***P≤0.001; ns, not significant. (C) Immunocytochemical staining of
VE-cadherin in HUVECs treated with growth factors for 4 and 24 h. Main
images are representative regions from the insets. Scale bars: 5 µm.
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Electrical resistance decreased upon BMP6 treatment in a time- and
dose-dependent manner (Fig. 1B, Fig. S1). A significant reduction
(P<0.05) was detected as early as 2 h after stimulation and
progressed over time, resulting in a 68±8% (mean±s.d.) reduction
after 24 h compared with untreated control cells (Fig. 1B).
Treatment of a HUVEC monolayer with VEGF-165 showed
similar effects (68±4%). Thus, both methods of choice
demonstrated a strong increase in permeability upon BMP6
stimulation.
Alterations of AJ architecture and, in particular, the localization
of VE-cadherin are the main regulators of vascular permeability.
Hence, we determined whether BMP6 treatment affects VE-
cadherin localization. A confluent HUVEC monolayer was
stimulated with BMP6 or VEGF-165 for 4 or 24 h and VE-
cadherin was visualized by immunofluorescence staining. VE-
cadherin staining in control cells showed close localization between
neighboring cells, indicating a narrow AJ architecture (Fig. 1C).
BMP6 stimulation led to ‘jagged’ VE-cadherin staining at 4 h and
pronounced disruption of cell–cell junctions at 24 h. VEGF-165
treatment resulted in a comparable staining pattern. This
demonstrated that BMP6 induces changes in AJ architecture
reflected in a jagged, rather than narrow, borderline of adjacent
cells. Taken together, our data showed that BMP6 treatment induces
endothelial cell hyperpermeability and the disruption of AJs.
BMP6 triggers internalization of VE-cadherin
An increase in vascular permeability and concomitant disruptions of
cell–cell contacts have been linked to internalization into subcellular
compartments and subsequent recycling or degradation of VE-
cadherin (Gavard and Gutkind, 2006). We therefore determined
whether BMP stimulation modulates the rate of VE-cadherin
endocytosis. We labeled VE-cadherin on sparse and confluent
HUVEC cultures using a specific monoclonal antibody (BV6)
targeting an extracellular epitope of VE-cadherin (Corada et al.,
2001). The cells showed a cell-surface staining that was sensitive to
acid wash (Fig. 2A, Fig. S2A). Although the BV6 antibody has been
described as increasing endothelial cell permeability (Corada et al.,
2001), we did not detect significant amounts of intracellular VE-
cadherin vesicles in control cells (Fig. 2A). This suggests that the
antibody exerts its effects by inhibition of VE-cadherin clustering at
37°C. However, upon 60 min of BMP6 treatment, an acid-resistant
intracellular VE-cadherin staining was observed in sparse
HUVECs, comparable to that observed under VEGF-165
stimulation conditions. Quantitation of labeled VE-cadherin
uptake normalized to untreated control cells revealed similar
effects for BMP6 and VEGF-165 treatment (Fig. 2B). Upon 4 h
of BMP6 or VEGF-165 treatment, similar observations were made
in confluent HUVECs (Fig. S2). From this we conclude that BMP6
induces VE-cadherin internalization.
To further investigate BMP6-induced internalization of VE-
cadherin, we biotinylated cell-surface proteins using Sulfo-NHS-SS
biotin (Gabriel et al., 2009). Subsequently, we allowed endocytosis
to occur for 60 min, stripped the remaining extracellular biotin and
measured the levels of biotinylated, internalized VE-cadherin.
Removal of biotinylated, cell-surface VE-cadherin was very
efficient, as demonstrated by stripping controls (stripping
efficiency of 92±7%, mean±s.d.) (Fig. 2C). Control cells
exhibited relatively low levels of internalized VE-cadherin (18%
of total VE-cadherin) and levels were increased upon BMP6
stimulation (50% of total) in a dose-dependent manner.
Quantitations showed that addition of 10 nM BMP6 resulted in a
1.4-fold increase in biotinylated internalized VE-cadherin
compared with untreated control cells, while 30 nM BMP6 led to
a 2.2-fold increase (Fig. 2D). Again, similar effects were observed
upon 2 nM VEGF-165 treatment (1.8-fold). These data showed that
addition of BMP6 to endothelial cells results in increased VE-
cadherin internalization.
BMP6 induces phosphorylation of VE-cadherin at Tyr685 by
activating c-Src
Besides its internalization, post-translational modifications of VE-
cadherin have been shown to regulate vascular permeability.
Recently, it was demonstrated that phosphorylation of VE-
cadherin at Tyr685 controls the opening of endothelial cell
junctions in vivo (Wessel et al., 2014). Hence, we analyzed
whether BMP signal transduction alters the phosphorylation status
of VE-cadherin. We immunoprecipitated VE-cadherin from BMP6-
stimulated or untreated HUVECs and analyzed the levels of VE-
cadherin phosphorylation at Tyr685 using a phospho-specific
antibody. Upon 30 min of BMP6 treatment, we observed a 6-fold
increase in the levels of phosphorylated VE-cadherin (Fig. 3A,B).
Thus, we concluded that BMP6 induces the phosphorylation of
VE-cadherin at Tyr685.
Next, we investigated the molecular mechanism underlying this
phosphorylation event. It has been shown that c-Src specifically
phosphorylates VE-cadherin at Tyr685 upon VEGF-165
stimulation in vitro (Wallez et al., 2007). We tested whether
BMP6 is able to activate c-Src in endothelial cells. We
immunoprecipitated c-Src from BMP6-stimulated or untreated
HUVECs and determined the levels of phosphorylation of c-Src
at Tyr416, an indicator for c-Src kinase activation. Control cells
exhibited a low baseline phosphorylation, whereas 15 min of BMP6
treatment resulted in a significant increase in the levels of
phosphorylated c-Src (P≤0.001; Fig. 3C). VEGF-165 was used as
a positive control as it has been demonstrated to activate c-Src in
cultured endothelial cells (Ha et al., 2008). Quantitation revealed a
3.4-fold and a 3.3-fold increase in phosphorylated c-Src levels
compared with control HUVECs for BMP6 and VEGF-165,
respectively (Fig. 3D). This showed that BMP signal transduction
triggers the activation of c-Src. Moreover, we demonstrated that
endogenous BMPRII and c-Src co-immunoprecipitate in HUVECs
and upon overexpression in HEK293T cells (Fig. 3E, Fig. S3A).
A similar approach demonstrated an association between ALK2,
which is the high-affinity BMPRI for BMP6, and c-Src upon
overexpression in HEK293T cells (Fig. 3F). These findings
suggested that c-Src interacts with the BMP–receptor complex
and its activity is regulated by BMP signal transduction.
To further dismantle the interplay of BMP signaling, we
performed knockdown experiments using siRNAs targeting ALK2
or SRC transcripts (Fig. S3B). We demonstrated that upon BMP6
treatment, VE-cadherin was phosphorylated at Tyr685 and this
phosphorylation was partially abrogated by knockdown of ALK2
(53% reduction) or SRC (85% reduction) (Fig. 3G). Similar, but less
pronounced, reductions were obtained with respect to c-Src
phosphorylation at Tyr416 (ALK2 knockdown, 30% reduction;
SRC knockdown, 67% reduction). Phosphorylation of SMAD1/5
was abrogated by knockdown of ALK2, but was unaffected in SRC
knockdown conditions. Furthermore, we observed comparable
results using small-molecule inhibitors targeting either ALK2
kinase (K02288) (Sanvitale et al., 2013) or Src family kinases (PP2)
(Hanke et al., 1996) (Fig. S3C). Taken together, these data
demonstrated that BMP signaling induces phosphorylation of
VE-cadherin at Tyr685 via BMP receptor-mediated activation of
c-Src.
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Since VE-cadherin phosphorylation is associated with increased
vascular permeability, we analyzed BMP6-induced changes in
TEER upon siRNA-mediated knockdown of ALK2 or SRC. BMP6
treatment triggered a decrease in electrical resistance in control cells
in a time-dependent manner (Fig. 3H). However, upon knockdown
of ALK2 or SRC this effect was significantly reduced, yet partial
permeabilization still occurred. Similar results were obtained when
ALK2 kinase was inhibited by K02288 or c-Src kinase activity was
blocked by PP2 (Fig. S3D). Taken together, our findings suggest
that BMP6-induced permeability requires ALK2 and, at least partly,
c-Src.
VE-cadherin facilitates BMP signal transduction
As we demonstrated an effect of BMP signal transduction on
VE-cadherin internalization and modification, we next examined
whether VE-cadherin in turn modulates BMP signaling in
endothelial cells. To assess the impact of VE-cadherin on BMP
signaling, we performed knockdown experiments in HUVECs
using siRNA targeting VE-cadherin (CDH5) mRNA (si-CDH5).
The knockdown efficiency at the protein level, as detected by
western blot, was 95±2% (mean±s.d.) compared with cells
transfected with non-targeting siRNA (si-scr) (Fig. 4A). Upon
stimulation with BMP6, a time-independent decrease in the levels of
phosphorylated (p)SMAD1/5 was detected (Fig. 4A). Quantitation
of pSMAD1/5 levels revealed significant 18% (P≤0.001) and 14%
(P≤0.001) reductions between si-scr-treated and si-CDH5-treated
cells upon 20 or 45 min treatment, respectively (Fig. 4B). This
suggested that VE-cadherin acts as a positive regulator of
endothelial BMP signal transduction.
As levels of pSMAD1/5 were decreased in VE-cadherin
knockdown conditions, we analyzed whether SMAD1/5-
dependent ID1 expression was also altered (Korchynskyi and ten
Dijke, 2002). We treated HUVECs with si-scr or si-CDH5,
stimulated with BMP6 for 60 min and then determined ID1
mRNA expression levels by qRT-PCR. We observed an increase
in ID1 expression levels between BMP6-treated and unstimulated
control cells, which was significantly decreased by 28% (P=0.042)
upon treatment with si-CDH5 (Fig. 4C). Treatment of HUVECs
Fig. 2. BMP6 stimulation increases internalization of VE-cadherin. (A) BMP6 increases the internalization rate of cell-surface-labeled VE-cadherin. HUVECs
were incubated with the VE-cadherin extracellular domain-targeting antibody BV6 at 4°C. VE-cadherin internalization was monitored by uptake of BV6 antibody
upon growth factor treatment for 60 min at 37°C. Remaining cell-surface antibodies, visible in ‘no acid wash’ conditions, were washed away with a mild acid
solution and internalized VE-cadherin antibodies were visualized in fixed cells by addition of a fluorophore-coupled secondary antibody (green). Blue, DAPI.
Scale bars: 20 µm. (B) Quantitation of VE-cadherin vesicles visible in A, normalized to untreated control cells. Mean±s.d. from three independent experiments.
(C) BMP6 triggers internalization of cell-surface biotinylated VE-cadherin. HUVEC surface proteins were biotinylated at 4°C and growth factor-induced
endocytosis was allowed to occur for 60 min at 37°C. Subsequently, remaining cell-surface biotin, which is visible in 4°C versus 4°C stripped samples, was
stripped at 4°C and cells were rinsed and solubilized. Internalized biotinylated proteins were subjected to immunoprecipitation and samples were blotted as
indicated. Total cell lysates (TCLs) represent samples before precipitation. Dotted line indicates merge of the same, but differentially exposed blot (left, 10 s; right,
60 s). (D) Quantitation of VE-cadherin signal intensities depicted in C and normalized to TCL VE-cadherin and untreated control cells. Mean±s.e.m. from four
independent experiments. (B,D) **P≤0.005, ***P≤0.001; ns, not significant.
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Fig. 3. BMP6 induces phosphorylation of VE-cadherin via activation of c-Src. (A) VE-cadherin is phosphorylated at Tyr685 upon BMP6 treatment. VE-
cadherin was immunoprecipitated with a VE-cadherin-specific antibody from confluent HUVECs treated with BMP6 for 30 min and samples were blotted as
indicated. Normal IgG antibody served as the immunoprecipitation (IP) control. TCLs represent lysates not subjected to IP. Dotted lines indicate where samples
from the same blot have been omitted. (B) Quantitation of pVE-cadherin_Tyr685 signal intensities depicted in A and normalized to TCL VE-cadherin and
untreated control cells. Mean±s.d. from four independent experiments. (C) c-Src kinase is activated upon BMP6 treatment. c-Src was immunoprecipitated with a
c-Src-specific antibody from confluent HUVECs treated with growth factors for 15 min. Normal IgG antibody served as an IP control. (D) Quantitation of
pSrc_Tyr416 signal intensities shown in C and normalized to TCL c-Src and untreated control cells. Mean±s.d. from three independent experiments. (E) BMPRII
interacts endogenously with c-Src. BMPRII was immunoprecipitated with a BMPRII-specific antibody from confluent HUVECs stimulated with BMP6 for 30 min
and samples were blotted as indicated. Quantitation shows the c-Src versus BMPRII IP signal intensity ratio. Normal IgG antibody served as an IP control. (F)
ALK2 associates with c-Src. HEK293T cells were transfected with ALK2-HA and c-Src, and HA-tagged ALK2 was immunoprecipitated with an HA-specific
antibody. Normal IgG antibody served as IP control. (G) ALK2 and c-Src are required for BMP-induced phosphorylation of VE-cadherin. HUVECs were
transfected with siRNA targeting either nonspecific sequences (si-scr), human ALK2 (si-ALK2) or human c-Src (si-SRC) and treated with BMP6 for 30 min. Cells
were lysed and blotted as indicated. (H) BMP6-induced permeability is mediated by ALK2 and c-Src. HUVECs were transfected with si-scr, si-ALK2 or si-SRC,
seeded in transwell inserts and stimulated with BMP6 for 24 h. At the indicated time points, TEERwasmeasured. Mean±s.d. normalized to untreated control cells
from three independent experiments. ***P≤0.001; ns, not significant. For BMP6-treated si-ALK2 and si-SRC versus untreated si-scr: ##P≤0.005, ###P≤0.001.
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with si-CDH5 resulted in an 87±2% (mean±s.d.) reduction of
CDH5mRNA (Fig. 4D). These data showed that the transcriptional
activity of SMAD1/5 is reduced upon knockdown of VE-cadherin.
The major function of VE-cadherin is to form clusters in a
transhomophilic manner between neighboring cells and to facilitate
the formation of cell–cell junctions. Hence, we examined whether
proper clustering of VE-cadherin at AJs is needed for endothelial
BMP6 signaling. The BV6 antibody has been described to block
homophilic interactions and dismantle VE-cadherin clusters
(Corada et al., 2001). Confluent HUVEC cultures treated with
BMP6 in the presence of the VE-cadherin-blocking antibody BV6
demonstrated decreased pSMAD1/5 levels compared with cells
treated with a nonspecific isotype IgG antibody (Fig. 4E).
Quantitation of pSMAD1/5 revealed a significant reduction by
26% (P≤0.001) upon BV6 treatment (Fig. 4F). Taken together,
these findings demonstrated that VE-cadherin positively regulates
BMP signal transduction and that proper VE-cadherin clusters at
cell–cell junctions are required for efficient signaling.
Fig. 4. VE-cadherin regulates endothelial BMP signaling. (A) VE-cadherin is required for efficient BMP signal transduction. HUVECs were transfected
with si-scr or si-CDH5 and treated with BMP6 for the indicated times. Cells were lysed and blotted as indicated. (B) Quantitation of pSMAD1/5 signal intensities
shown in A and normalized to GAPDH and untreated control cells. Mean±s.d. from three independent experiments. (C) VE-cadherin is required for optimal
activation of SMAD1/5 target gene expression. HUVECs were transfected with si-scr or si-CDH5 and treated with BMP6 for 60 min. ID1 mRNA expression was
determined using qRT-PCR and normalized to GAPDH control mRNA expression and to untreated control cells. Mean±s.e.m. from three independent
experiments. (D)CDH5mRNA expression was determined after siRNA transfection using qRT-PCR and normalized toGAPDH control mRNA expression and to
si-scr-treated control cells. Mean±s.e.m. from three independent experiments. (E) VE-cadherin clusters are needed for efficient BMP signaling. HUVECs were
incubated with the VE-cadherin extracellular domain-targeting antibody BV6 or isotype control antibody and treated with BMP6 for 45 min. Cells were lysed and
blotted as indicated. (F) Quantitation of pSMAD1/5 signal intensities depicted in E and normalized to GAPDH and untreated control cells. Mean±s.d. from three
independent experiments. **P≤0.005, ***P≤0.001. For BMP6-treated si-scr and si-CDH5: #P≤0.05, ###P≤0.001.
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VE-cadherin associates with the BMP–receptor complex
We have shown that VE-cadherin regulates BMP6-induced
phosphorylation of SMAD1/5 and downstream transcriptional
activity. It has previously been reported that VE-cadherin forms
complexes with structurally related TGF-β receptors (Rudini et al.,
2008) and thus we hypothesized that VE-cadherin might also
interact with the related BMP receptors. To test this in intact cells,
we made use of an in situ proximity ligation assay (PLA). HUVECs
were either stimulated with BMP6 for 60 min or left untreated.
Subsequently, cells were fixed and probed with antibodies targeting
intracellular epitopes of either ALK2 or BMPRII in combination
with VE-cadherin. Heteromers were visualized by proximity-
dependent ligation of species-specific, oligonucleotide-conjugated
secondary antibodies, followed by incubation with a fluorescent
probe. Cells that were not treated with ligand had few ALK2–VE-
cadherin or BMPRII–VE-cadherin heteromers (Fig. 5A), whereas
cells exposed to BMP6 showed a higher number of heteromers for
both ALK2–VE-cadherin (2-fold, P=0.004) and BMPRII–VE-
cadherin (2.3-fold, P≤0.001) heteromers (Fig. 5B). This suggested
that VE-cadherin physically associates with BMP type I and type II
receptors in a ligand-dependent manner.
To confirm this interaction, we immunoprecipitated VE-cadherin
from confluent HUVECs that were stimulated with BMP6 for
60 min or left untreated and then were analyzed for associated
BMPRII. Complex formation between VE-cadherin and BMPRII
was already detectable in control HUVECs, but the interaction
increased upon ligand addition (Fig. 5C). These VE-cadherin–
BMPR complexes were further validated by overexpression of HA-
tagged BMPRII or ALK2 in combination with VE-cadherin in
HEK293T cells followed by immunoprecipitation of VE-cadherin
(Fig. 5D,E).
BMP signal transduction is initiated upon ligand-induced
activation of the heteromeric BMP type I and type II receptor
complex. As VE-cadherin interacted with both receptor types in a
ligand-dependent fashion and positively regulated downstream
signaling, we hypothesized that VE-cadherin is needed for proper
BMP receptor complex assembly. To address this question, we
overexpressed HA-tagged ALK2 and Myc-tagged BMPRII in the
absence or presence of co-expressed VE-cadherin in HEK293T
cells and stimulated with BMP6 for 45 min. Subsequently,
BMPRII-Myc was immunoprecipitated and protein levels of
associated ALK2-HA and VE-cadherin were determined. In the
absence of VE-cadherin, a low degree of receptor oligomerization
was observed in BMP6-treated cells (Fig. 5F, lanes 1 and 2). This
interaction was increased remarkably when VE-cadherin was co-
expressed and ligand-dependent complex formation between
ALK2, BMPRII and VE-cadherin was detected (Fig. 5F, lane 4).
These data demonstrated that VE-cadherin physically associates
with ALK2 and BMPRII in a ligand-dependent manner in
endothelial cells and stabilized BMP receptor complex formation.
DISCUSSION
Vascular BMP signaling regulates physiological as well as
pathological processes in the endothelium, yet a detailed
molecular analysis of its influence on vascular permeability is
missing. Here, we provide evidence that BMP6 increases
permeability in vitro and unravel a hitherto undescribed
regulatory mechanism of vascular BMP signal transduction
involving VE-cadherin.
We measured solute flux and electrical resistance across a
HUVEC monolayer to assess alterations in permeability and
showed that BMP6 induces hyperpermeability similar to VEGF in
a time- and dose-dependent manner. Pharmacological inhibition of
the BMP6 type I receptor ALK2 demonstrated that this process
requires activation of the BMP receptor complex. These findings are
in line with a recent study showing that BMP2 induces permeability
of retinal endothelial cells (Hussein et al., 2014). BMP2 was
upregulated in human and murine diabetic retinas and promoted
permeability in a time-dependent manner. Moreover, BMP2-
induced hyperpermeability was also reported in lung epithelial
cells (Helbing et al., 2013). BMP2 was upregulated in injured lung
epithelium and caused increased solute permeability of cultured
bronchial epithelial cells via activation of SMAD1/5-ID1 signaling
and downregulation of E-Cadherin. The authors of that study
concluded that excessive BMP activity is involved in the disruption
of epithelial barrier function after lung injury. This assumption is
consistent with other published studies that relate BMP signaling to
disturbed barrier function. During acute inflammation, increased
vascular permeability is one of the first events to take place in order
for plasma proteins, fluids and immune cells to reach the injured
tissue. Several reports indicate that BMP signaling is activated
during inflammation and atherosclerosis and increased monocyte
adhesion to endothelial cells has been observed upon BMP
treatment (Rosendahl et al., 2002; Sorescu et al., 2003, 2004;
Helbing et al., 2011; Derwall et al., 2012; Lee et al., 2012).
Another process that involves opening of the endothelial barrier is
metastasis. During metastasis, disseminated cancer cells extravasate
from the bloodstream to invade surrounding tissues and organs. It is
well known that BMPs enhance the invasiveness of cancer cells in
vitro and in vivo (Thawani et al., 2010) and BMP6 expression
correlates with the metastatic potential of prostate cancer (Hamdy
et al., 1997). Furthermore, patients with hereditary pulmonary
arterial hypertension (PAH) exhibit endothelial cell dysfunction and
vascular leakage that have been linked to heterozygous BMPR2
mutations (Prewitt et al., 2015). These observations highlight the
implications of perturbed BMP signaling in diseases associated with
impaired endothelial barrier function. However, in vivo studies
demonstrating the importance of BMP-induced vascular
permeability are still lacking, and future studies are required to
gain further mechanistic insight.
In our study, we demonstrated that endothelial AJ architecture is
dramatically altered upon BMP6 or VEGF stimulation, as VE-
cadherin staining revealed a jagged borderline with visible openings
between neighboring cells. These types of cell–cell contacts have
been termed remodeling junctions (Huveneers et al., 2012), and
changes in VE-cadherin localization at AJs have been repeatedly
attributed to the control of vascular permeability (Dejana et al.,
2008). A well-described cause for these changes is the
internalization of VE-cadherin into intracellular vesicles, thereby
removing it from the cell surface. This results in the reversible
disruption of cell–cell junctions until surface levels of VE-cadherin
are restored. We show that BMP6 triggers the internalization of VE-
cadherin in a dose-dependent manner in HUVECs at similar rates as
VEGF. Gavard and Gutkind (2006) reported that VEGF induces β-
arrestin 2-dependent endocytosis of VE-cadherin and showed that a
specific serine residue (Ser665) within the cytoplasmic domain of
VE-cadherin was phosphorylated upon VEGF treatment, served as a
docking site for β-arrestin 2 and regulated solute permeability in
cultured endothelial cells. Although β-arrestin 2-mediated
endocytosis has been mainly linked to G-protein-coupled receptor
(GPCR) signaling, a few studies describe its function in the
internalization of other cell-surface proteins, such as insulin-like
growth factor I receptor (IGF1R) (Lin et al., 1998). Interestingly,
a study by Chen et al. (2003) provided evidence for β-arrestin
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2-mediated endocytosis of the TGF-β type III receptor betaglycan
(also known as TGFβR3). They reported that internalization was
initiated upon phosphorylation of a specific threonine residue
(Thr841) within the cytoplasmic domain of betaglycan by the
TGF-β type II receptor kinase. This finding suggests that serine/
threonine kinase receptors of the TGF-β family promote β-arrestin
2-dependent endocytosis by phosphorylation of specific residues
within their targets. Whether VE-cadherin contains serine/
threonine residues that can be phosphorylated by the BMP
receptors and whether these modifications initiate β-arrestin-
mediated internalization to control vascular permeability, similar
to VEGF, remains unknown at present.
Fig. 5. VE-cadherin interacts withBMP receptors. (A) In situ proximity ligation assay (PLA) of VE-cadherin and the BMP receptors ALK2 and BMPRII. HUVECs
were treated with BMP6 for 60 min and association of VE-cadherin and ALK2 or BMPRII was visualized using an in situ PLA (green). DAPI, blue. Scale bars:
10 µm. (B) Quantitation of VE-cadherin–ALK2 and VE-cadherin–BMPRII heteromers shown in A. Mean±s.d. from three independent experiments. (C) VE-
cadherin interacts endogenously with BMPRII. VE-cadherin was immunoprecipitated with a VE-cadherin-specific antibody from confluent HUVECs stimulated
with BMP6 for 60 min and samples were blotted as indicated. Recombinant protein A-Sepharose beads served as an IP control. TCLs represent lysates not
subjected to immunoprecipitation. (D) VE-cadherin associates with BMPRII upon overexpression. HEK293T cells were transfected with VE-cadherin and
BMPRII-HA, and VE-cadherin was immunoprecipitated with a VE-cadherin-specific antibody. Normal IgG antibody served as IP control. (E) VE-cadherin
associates with ALK2 upon overexpression. HEK293T cells were transfected with VE-cadherin and ALK2-HA, and VE-cadherin was immunoprecipitated with a
VE-cadherin-specific antibody. Normal IgG antibody served as IP control. (F) VE-cadherin facilitates BMP receptor complex formation. HEK293T cells were
transfected with BMPRII-Myc and ALK2-HA in the absence or presence of co-expressed VE-cadherin. Cells were stimulated with BMP6 for 45 min, followed by
immunoprecipitation of Myc-tagged BMPRII with a Myc-specific antibody. Mouse IgG isotype antibody served as IP control. **P≤0.005, ***P≤0.001.
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Another mechanism that impairs endothelial barrier function is
the tyrosine phosphorylation of VE-cadherin, which promotes the
remodeling of AJs. Multiple permeability-increasing agents, such
as VEGF (Esser et al., 1998), TNF-α (Angelini et al., 2006) or
histamine (Andriopoulou et al., 1999), induce tyrosine
phosphorylation of VE-cadherin in vitro. However, conflicting
data exist about which specific VE-cadherin tyrosine residue
(Tyr658, Tyr685, Tyr731) becomes phosphorylated in cultured
endothelial cells (Potter et al., 2005;Wallez et al., 2007; Adam et al.,
2010). Using knock-in mouse models, two recent studies elegantly
revealed that VE-cadherin phosphorylation at Tyr685 controls
vascular permeability, whereas phosphorylation at Tyr731 regulates
leukocyte extravasation (Sidibe et al., 2014; Wessel et al., 2014).
Thus, we addressed whether BMP signaling induces
phosphorylation of VE-cadherin and showed that, upon BMP6
stimulation of HUVECs, VE-cadherin is phosphorylated at Tyr685.
A peptide-mapping approach on the cytoplasmic domain of VE-
cadherin indicated that Tyr685 is specifically phosphorylated by c-
Src (Wallez et al., 2007). This finding is in line with several other
studies that demonstrate an involvement of c-Src in VEGF-induced
vascular permeability (Eliceiri et al., 1999; Gavard et al., 2008; Ha
et al., 2008).
Here, we provide evidence for a BMP6-induced activation of
c-Src in an ALK2 kinase-dependent manner in HUVECs. We
show that ALK2 and c-Src are required for phosphorylation of
VE-cadherin at Tyr685. Moreover, we demonstrate a physical
interaction of c-Src and ALK2 as well as BMPRII and that c-Src
becomes activated upon receptor complex formation and in turn
phosphorylates downstream targets at specific tyrosine residues.
These observations are in contrast to a recent study demonstrating
that mice carrying heterozygous null mutations of Bmpr2 in
pulmonary endothelial cells show constitutive activation of Src
kinase and that this effect can be reversed by BMP2 stimulation
(Prewitt et al., 2015). Furthermore, BMP signaling was shown to
inhibit Src activation in pulmonary smooth muscle cells, but large
differences in inhibition potential were seen between different
BMPs, and BMP7, a member of the same BMP subgroup as BMP6,
only had a mild effect on Src kinase inhibition (Wong et al., 2005).
The authors also showed a BMPRII–Src interaction using a yeast
two-hybrid approach and overexpression in HEK293T cells, yet this
interaction has thus far not been reproduced in any other cell type.
Hence, these studies and our findings strongly indicate that BMP-
dependent regulation of Src activity is ligand- and context-
dependent and might require hitherto unidentified effectors.
However, in line with the study by Prewitt et al. (2015), we
assume that Src activity is, at least in part, regulated by BMPRII. As
we and others have shown previously, BMP and TGF-β type II
receptors carry dual kinase activity (Lawler et al., 1997), leading to
cis and trans phosphorylation at serine, threonine and tyrosine
residues. Tyrosine-phosphorylated BMPRII might act as a docking
site for c-Src, as previously suggested by Wong et al. (2005).
Furthermore, in silico analysis shows that the C-terminal domain of
BMPRII contains putative binding sites for Src homology 3 (SH3)
domains that could explain the binding of c-Src to BMPRII in a
tyrosine phosphorylation-independent manner. Future studies
should address the exact nature of this interaction, especially
considering the conflicting data on the resulting effects.
Besides describing its influence on endothelial cell permeability,
we report a novel regulatory mechanism of vascular BMP signal
transduction by VE-cadherin. We showed that VE-cadherin
knockdown in HUVECs decreases BMP signaling activity and
that proper VE-cadherin clustering at endothelial cell–cell junctions
is required for efficient local BMP signal transduction. As VE-
cadherin interacts with ALK2 and BMPRII in a ligand-dependent
manner, we propose a stabilizing function of VE-cadherin for BMP
receptor complexes in endothelial cell junctions. Interestingly,
results from PLAs suggested that BMP receptors associate with VE-
cadherin in intracellular vesicles. We have previously shown that
both BMPRI and BMPRII undergo clathrin-mediated endocytosis,
but caveolin-dependent internalization was only observed for
BMPRII (Hartung et al., 2006). It has been reported that VE-
cadherin is internalized via clathrin-coated pits by a p120-catenin-
dependent mechanism (Xiao et al., 2005). Besides, VE-cadherin
recruits caveolin-1 to endothelial cell junctions and phosphorylated
caveolin-1 weakens VE-cadherin–catenin interactions and thus
regulates endothelial barrier function (Kronstein et al., 2012).
Furthermore, a recent study demonstrated that heterozygous null
Bmpr2 mutations affect Src-dependent, caveolin-dependent
internalization as well as the phosphorylation of caveolin-1
(Prewitt et al., 2015). These observations indicate that BMP-
induced permeability may be differentially regulated by clathrin-
and caveolin-dependent endocytosis mechanisms.
In this study, we show that VE-cadherin acts as a positive regulator
of endothelial BMP signal transduction, which is consistent with a
previous study describing a similar role of VE-cadherin in TGF-β
signaling (Rudini et al., 2008). It was shown that VE-cadherin
interacts with the TGF-β receptor complex and facilitates
oligomerization of the complex in a ligand-dependent fashion
(Rudini et al., 2008). Moreover, using VE-cadherin knockout
endothelial cells, the authors showed that VE-cadherin acts as a
positive regulator of endothelial TGF-β signal transduction and found
that proper VE-cadherin clustering is needed for efficient signaling.
These observations suggest that VE-cadherin physically associates
with receptors of the TGF-β family to stabilize their oligomerization
and increase downstream signaling. This stands in contrast to the VE-
cadherin-mediated inhibition of VEGF-VEGFR2 signal transduction
in confluent endothelial cells. It has been shown that VEGFR2 is
dephosphorylated and its internalization strongly reduced upon
association with VE-cadherin (Lampugnani et al., 2006). The net
effect was an inhibition of cell proliferation by decreasing efficient
VEGFR2 signaling. The authors proposed that this regulatory
mechanism modulated the capacity of cells to proliferate and
survive in a density-dependent manner, thereby controlling contact
inhibition of growth in vitro. In combination with the finding that
TGF-β-induced inhibition of cell migration and proliferation was
enhanced in the presence of VE-cadherin (Rudini et al., 2008), these
observations strongly support the idea that VE-cadherin modulates
growth factor receptor signaling in favor of vessel stability.
However, the BMP6-induced hyperpermeability and the positive
effects of VE-cadherin on BMP signaling in vitro that we describe
seem to contradict this idea. The effects of BMP6 on endothelial
cells are less well characterized compared with other BMP family
members, such as BMP2 and BMP9. Dose-dependent binding of
distinct BMP ligands causes the recruitment and a unique mode of
oligomerization of specific BMP receptors, which is crucial for the
induction of individual downstream signaling pathways and a
hallmark of this signal transduction pathway (Ehrlich et al., 2012). It
has been reported that BMP6 activates endothelial cells by
induction of cell migration and tube formation (Valdimarsdottir
et al., 2002). These findings are in line with our results showing
BMP6-induced activation with respect to HUVEC permeability.
However, BMP9 has been reported to inhibit the proliferation and
migration of endothelial cells induced by basic fibroblast growth
factor (bFGF, also known as FGF2) (Scharpfenecker et al., 2007),
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indicating ligand-dependent outcomes. Similar phenomena were
observed upon TGF-β stimulation in several studies. It has been
shown that upon TGF-β inhibition by overexpression of soluble
endoglin, mouse retinal permeability was increased (Walshe et al.,
2009). However, Behzadian et al. (2001) demonstrated that TGF-β
stimulation of bovine retinal cells induces hyperpermeability via
activation of matrix metalloproteinase 9 (MMP9) (Behzadian et al.,
2001). Moreover, TGFβ1 has been shown to regulate bFGF- and
VEGF-induced endothelial cell invasion and tube formation in a
dose-dependent manner. High doses had an inhibitory effect,
whereas low doses potentiated the effects of bFGF and VEGF in
bovine microvascular cells (Pepper et al., 1993). Interestingly,
Goumans et al. (2002) provided evidence that the activation state of
endothelial cells is regulated by TGF-β in vitro. Cell migration and
proliferation were activated by ALK1–Smad1/5 signaling, whereas
ALK5–Smad2 had an inhibitory effect. These observations
demonstrate that vascular BMP/TGF-β signal transduction is
ligand-, dose- and context-dependent, and that further clarification
is needed, especially considering the regulation by VE-cadherin.
In the present study, we demonstrate that BMP6 induces
endothelial cell permeability in vitro and provide mechanistic
insight by showing that BMP signaling remodels AJ architecture by
promoting the internalization and modification of VE-cadherin. Our
study suggests that endothelial BMP signaling is modulated by VE-
cadherin and controls barrier function (Fig. 6). Further studies
should pave the way for novel therapies in the context of acute
inflammation, atherosclerosis, metastasis and multiple other
pathologies associated with increased vascular permeability.
MATERIALS AND METHODS
Reagents and antibodies
All chemicals were purchased fromSigma-Aldrich, unless otherwise indicated.
Production of recombinant human BMP6 was described previously (Simic
et al., 2006; Vukicevic et al., 2014). BMP6 used in the experiments has been
produced under collaborative FP7 health project Osteogrow (grant agreement
number 279239) by GMP manufacturing for clinical trials in patients for bone
regeneration. The BMP6 producer cell line is CHODG44, suspension adapted,
transduced by a lentivirus vector with advanced safety features. Lentivirus
vector was chosen for its unique features allowing highly efficient, multicopy,
stable transduction of genes into growing and stationary cells (Lentigen
Corporation). BMP6 was purified using heparin Sepharose, then phenyl
Sepharose, and finally subjected to C18 RP-HPLC, analyzed under GMP
conditions (Biochem) and found free of endotoxins and host cell proteins (SGS
Vitrology). Investigational medicinal product dossier (IMPD) has been
approved by national regulatory agencies in Austria and Croatia. In a
standardized in vitro assay using C2C12 cells, BMP6 has been compared with
protein from R&D Systems and had a similar biological potency. BMP6 was
used at 10 nM, unless otherwise indicated. Recombinant human VEGF-165
was purchased from ImmunoTools and used at 2 nM. LDN-193139was a kind
gift of Paul B. Yu (Boston, USA) (Cuny et al., 2008) and Alex N. Bullock
(Oxford, UK) kindly provided K02288 (Sanvitale et al., 2013).
The following antibodies were purchased from Cell Signaling
Technology: rabbit anti-VE-cadherin (D87F2), rabbit anti-phospho-
SMAD1/5 (Ser463/465) (41D10), rabbit anti-GAPDH (14C10), rabbit
anti-phospho-Src family (Tyr416) (D49G4), rabbit anti-Src (36D10), rabbit
anti-BMPR2, rabbit anti-ACVR1 (ALK2), mouse anti-Myc (9B11), mouse
IgG1 isotype control (G3A1) and normal rabbit IgG. In addition, mouse
anti-human VE-cadherin (BV6, Enzo Life Sciences), goat anti-VE-cadherin
(C-19, Santa Cruz), rabbit anti-phospho-VE-cadherin (Tyr685, ECM
Biosciences) and mouse anti-HA (HA-7, Sigma-Aldrich) were used. For
western blot analysis, all antibodies were used at 1:1000.
Cell culture and transfections
HUVECs were a kind gift from M. Lorenz, V. Stangl and A. Pries (Berlin,
Germany) and cultured on gelatin-coated tissue culture ware (Greiner Bio-
One) in M199 medium (Sigma-Aldrich; with Earle’s salts and NaHCO3)
supplemented with 20% fetal calf serum (FCS) (Biochrom), 50 µg/ml
endothelial cell growth supplement (Corning), 25 µg/ml heparin, 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (herein referred
to as HUVEC growth medium) at 37°C and 5% CO2. HUVECs were used
between passage two to five from isolation. Unless indicated otherwise,
HUVECs were starved for 6 h prior to stimulation in M199 medium (with
Earle’s salts and NaHCO3) supplemented with 2 mM L-glutamine and
100 U/ml penicillin and 0.1 mg/ml streptomycin (herein referred to as
HUVEC starvation medium).
Pharmacological inhibitors (LDN-193189, K02288 or PP2) were added
60 min prior to stimulation. Equal volumes of dimethylsulfoxide (DMSO)
were used to treat control cells.
For knockdown, 40 nM commercially available siRNA against ALK2
(herein referred to as si-ALK2), c-Src (si-SRC) and VE-cadherin (si-CDH5)
(ON-TARGETplus SMARTpool, GE Healthcare) was transfected in
Fig. 6. Model of BMP6-induced
vascular permeability. At
endothelial cell AJs, BMP6 induces
receptor complex assembly, activates
c-Src via phosphorylation at Tyr416
and promotes c-Src-dependent
phosphorylation of VE-cadherin at
Tyr685 (red arrows). In addition, BMP
signaling induces VE-cadherin
internalization (purple arrows).
Collectively, these mechanisms
trigger AJ remodeling and ultimately
result in hyperpermeability (red and
purple box). Moreover, VE-cadherin
functions as a positive regulator of
vascular BMP signal transduction.
Clustered VE-cadherin is needed for
efficient signaling and stabilizes the
ALK2–BMPRII receptor complex
(blue arrow), thus facilitating SMAD1/
5-dependent signaling (blue box).
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HUVECs using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions. ON-TARGETplus non-targeting siRNA
(herein referred to as si-scr, GE Healthcare) was used as a control.
HEK293T cells (American Type Culture Collection) were cultured and
transfected as previously described (Hiepen et al., 2014).
Expression plasmids
The full-length coding sequence of human VE-cadherin was amplified from
HUVEC cDNA and cloned into the pcDNA3.1 mammalian expression
vector using TOPO-TA cloning (Life Technologies) according to the
manufacturer’s instructions. The plasmids encoding BMPRII-HA and
BMPRII-Myc were described previously (Gilboa et al., 2000). The C-
terminally HA-tagged human ALK2 (ALK2-HA) expression plasmid was
kindly provided by K. Miyazono (Tokyo, Japan). Full-length c-Src
expression plasmid was kindly provided by R. Lefkowitz (Durham, USA)
and is described elsewhere (Luttrell et al., 1999). All plasmids were verified
by DNA sequencing.
RNA extraction and qRT-PCR
HUVEC total RNA was isolated as previously described (Bhushan et al.,
2013). Quantitative (q) RT-PCR was performed using SYBR Green
Mix and the StepOne Plus Real-Time PCR System (Applied Biosystems).
The following human-specific primer sets were used (5′-3′, forward and
reverse): ID1, GCTGCTCTACGACATGAACG and CCAACTGAAGGT-
CCCTGATG; CDH5, CAGCCCAAAGTGTGTGAGAA and CGGTCA-
AACTGCCCATACTT; GAPDH, GAAGGTGAAGGTCGGAGTC and
GAAGATGGTGATGGGATTTC. The ΔΔCt method was used to
quantify mRNA expression relative to GAPDH.
Immunoprecipitation and western blot analysis
Immunoprecipitation of endogenous proteins from HUVECs was performed
using TNE lysis buffer freshly supplemented with 0.5% Triton X-100, 1 mM
PMSF (Carl Roth), 20 mM sodium pyrophosphate, 50 mM sodium fluoride,
300 µM freshly prepared sodium pervanadate and 1× Complete EDTA-free
Protease Inhibitor Cocktail (Roche). Immunoprecipitation of overexpressed
proteins from HEK293T cells was performed using a modified
radioimmunoprecipitation assay buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 0.5% NP-40, 0.1% SDS) freshly supplemented with inhibitors as
described above. Following lysis, lysates were centrifuged at 4°C for 20 min at
16,000 g and pre-cleared at 4°C for 30 min with recombinant protein A-
agarose beads (Thermo Scientific). Aliquots were then set aside for direct blot
analysis [total cell lysates (TCLs)] and aliquots for immunoprecipitation
(IP) were incubated at 4°C for 2 h or overnight with the indicated antibodies
(5 μg/ml). Control samples were either incubated with isotype control
antibodies or recombinant protein A-Sepharose beads (GE Healthcare).
Immunocomplexes were precipitated at 4°C for 2 h with recombinant protein
A-Sepharose beads (GE Healthcare) and subsequently washed three to five
times with fresh lysis buffer including inhibitors. Proteins were eluted with 2×
Laemmli sample buffer and heated for 10 min at 95°C.
Protein lysates were blotted and analyzed as previously described (Hiepen
et al., 2014). Quantitation of signal intensities was performed using Bio1D
software (Vilber Lourmat) or Image Studio Lite software (LI-COR
Biosciences) and normalized to loading control or IP TCL and untreated
control samples.
Immunofluorescence microscopy
HUVECs were seeded at 200,000 cells/cm2 in HUVEC growth medium in
µ-Slide 8-well (ibidi) dishes 24 h prior to the experiment. After 4 h of serum
starvation in HUVEC starvation medium containing 1% FCS, cells were
stimulated with the indicated growth factors at 37°C for 4 or 24 h.
Subsequently, cells were fixed, quenched and permeabilized with 0.3%
Triton X-100. After blocking, cells were incubated with the indicated
primary antibodies (1:200), followed by detection using Alexa Fluor-
coupled secondary antibodies (Life Technologies). Nuclei were
counterstained using DAPI (Carl Roth). Images were taken with a
CoolSnap-HQ2 CCD camera (Roper Scientific) mounted to an inverted
epifluorescence Axiovert 200M microscope (Carl Zeiss) and analyzed with
Axiovision (Carl Zeiss) and Corel DRAW X4 (Corel) software.
Cell-surface biotinylation
The cell-surface biotinylation protocol is described by Gabriel et al. (2009).
In brief, HUVECs were seeded at 20,000 cells/cm2 in HUVEC growth
medium 48 h prior to the experiment, serum-starved in HUVEC starvation
medium containing 2% FCS for 6 h at 37°C. Subsequently, cells were either
stimulated with the indicated growth factors for 60 min at 37°C or left at 4°C
for total cell-surface control samples. Biotinylation using cell-impermeable
sulfosuccinimidyl-6-(biotinamido)hexanoate (EZ-Link Sulfo-NHS-SS-
Biotin, Thermo Scientific) and subsequent processing were performed as
previously described (Gabriel et al., 2009).
Internalization assay
Internalization of VE-cadherin was measured as previously described (Xiao
et al., 2003b). In brief, HUVECs were seeded at 50,000 cells/cm2 (sparse) or
200,000 cells/cm2 (confluent) in HUVEC growth medium in µ-Slide 8-well
dishes 24 h prior to the experiment. After serum starvation, cell-surface VE-
cadherin was labeled at 4°C with the extracellular VE-cadherin domain-
targeting antibody BV6 for 60 min, rinsed with ice-cold PBS and stimulated
with recombinant growth factors at 37°C. Then, cells were subjected to a
mild acid wash and internalized VE-cadherin was visualized using
immunofluorescence microscopy as described above. Internalized VE-
cadherin vesicles from at least ten images per experimental condition were
quantified using BlobFinder image analysis software as previously
described (Allalou and Wählby, 2009). The results were normalized to
untreated control cells.
In situ proximity ligation assay
HUVECs were seeded at 200,000 cells/cm2 in HUVEC growth medium in
Nunc Lab-Tec II 16-well glass chamber slides (Thermo Scientific). Cells
were serum-starved for 2 h in HUVEC starvation medium, followed by
stimulation with the indicated growth factors for 60 min. Subsequently,
Duolink in situ proximity ligation (Sigma-Aldrich) was performed as
previously described (Thymiakou and Episkopou, 2011). The number of
heteromers was quantified using BlobFinder image analysis software as
previously described (Allalou andWählby, 2009). At least 15-20 images per
experimental condition were quantified and normalized to untreated control
cells.
Transendothelial solute permeability
HUVEC monolayer solute permeability was determined using an in vitro
vascular permeability 96-well assay kit (Merck Millipore) according to the
manufacturer’s instructions. HUVECs were stimulated with the indicated
growth factors for 24 h and monolayer solute permeability was determined
by addition of a high molecular weight FITC-Dextran (Merck Millipore) and
subsequent measurement of fluorescence intensity using aMithras microplate
reader (Berthold Technologies). Fluorescence intensity was measured in
duplicate per condition and normalized to untreated control cells.
Transendothelial electrical resistance (TEER)
HUVECs were seeded at 200,000 cells/cm2 in HUVEC growth medium on
fibronectin/collagen-coated Costar 24-well transwell inserts (0.4 µm
polyester membrane, Corning) 72 h prior to the experiment. Cells were
then serum-starved for 4 h in HUVEC starvation medium containing 2%
FCS and stimulated with the indicated growth factors. TEER was measured
at the indicated time points using a Millicell ERS-2 Voltohmmeter (Merck
Millipore). Then, blank TEER values, measured in transwell inserts without
cells, were subtracted, resistance per cm2 was calculated and normalized to
untreated control cells at the start of stimulation (0 h).
VE-cadherin declustering
Declustering of VE-cadherin was performed as previously described
(Rudini et al., 2008). Antibodies were used at 50 µg/ml.
Statistical analysis
Statistical analysis was performed by unpaired Student’s t-test or variance
analysis using SigmaPlot software (Systat Software). P<0.05 was
considered statistically significant.
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